INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by chronic, symmetry, polysynovitis and inflammation of joints. The incidence of RA is~1% in the world population and it is significantly more prevalent in women than in men (3:1 ratio). 1, 2 It was usually caused by multiple genetics and environment factors, but the pathogenesis and etiology of RA were not well understood to date. Genome-wide association study (GWAS) had been successfully applied in RA and identified some risk loci related to RA. For example, the first effective application of the GWAS in RA was to identify the association at TNFAIP3. Plenge et al. 3 identified an associated single-nucleotide polymorphism (SNP) (rs10499194) in this region using a collection of Bostonbased cases and controls. Thomson et al. 4 discovered another TNFAIP3-associated SNP (rs6920220) in the follow-up study of the Wellcome Trust Case Control Consortium (WTCCC) RA GWAS study. With the deepening of the research, people find the risk SNPs discovered by GWAS were too few to explain complex genetic structure of RA for the following reasons. First, the common method of the current GWAS was to choose significant SNPs according to the threshold for further analysis. 5 However, some SNPs that did not reach the threshold but were actually associated with RA could not be discovered. These SNPs usually had modest effect on RA. [6] [7] [8] Second, the ultimate goal of genetic study of RA is to explain molecular mechanism of RA from genotype to phenotype. 5, 9 The pathways or biological functions, which were identified by pathway-based analysis, can achieve this goal. Loci and genes are not isolated and usually play a role by their joint actions in the pathways or networks. 10 With the continuous development of systems biology and constantly emerging of high-throughput omics data, it will be a challenge to use innovative bioinformatics methods based on GWAS to explain the pathogenesis of RA from the aspect of biology functions. 11, 12 Pathway-based GWAS study was proposed as an improvement association study to unravel complex genetic structure of diseases. Pathway-based analysis was to take a pathway as a basic unit of analysis and took fully into account the interaction between the modest genes. It did not only make up the limitations caused by GWAS, but also could account for genetic variation of RA systematically. Complex diseases are usually caused by accumulative effect of DNA variation in the pathway or biology processes. 13 Therefore, pathways associated with diseases may unravel pathogenesis of complex diseases. Pathway-based analysis can identify risk pathways and allow to gain insight into the functional basis of the association. 5, 14, 15 This method had been applied into several diseases successfully and had identified some risk pathways related to the diseases. 7, 10, 16, 17 Further researches of these results will help us to uncover the mechanism of complex diseases.
Pathway information is very important for understanding the function of genes and proteins. Therefore, we applied pathwaybased association analysis to two RA GWAS data sets to identify RA-risk pathways based on the accumulation of genetic variation in the pathway. The two RA GWAS data sets were from GAW16 (Genetic Analysis Workshop 16) and WTCCC. 18, 19 We first calculated P-values of all SNPs by trend test. Next, all SNPs in each GWAS data set were mapped to autosomal genes. To make the results more reliable, we adopted five mapping intervals, which were 0 bp, 10, 20, 50 and 100 kb. We assessed gene-wise risk values using the minimum P-value method and calculated pathway scores according to gene-wise risk values in the same pathway. RA-risk pathways were identified by permutation test. Finally, we merged the results from the two pathway-based genome-wide association analyses to identify the high-risk pathways, which were found in both the data sets.
RESULTS

Consistency analysis of two permutation methods
Fisher combination method and adjusted Fisher combination method were adopted to calculate pathway scores. Permutation tests corresponding to the two methods were used to identify risk pathways associated with RA. We analyzed the correlation relationship between the P-values obtained by two methods and found that the correlation of P-values obtained by two methods was significant in each gene interval in each data set. Specially, when genes upstream and downstream were extended 20 kb, the correlation coefficient of P-values obtained by permutation tests based on the two methods is 0.996 (P-value o2.2e − 16) in GAW16 data set and 0.999 (P-value = 0) in WTCCC data set. Scatter diagram of P-values obtained by two methods in 20 kb is shown in Figure 1 . This indicates that the two methods are equivalent. Thus, we chose Fisher combination method to identify RA-risk pathways.
The results of GAW16 There were 5 31 027 SNPs passed quality control in GAW16. After mapping SNPs to genes, we found that there were 18 676 genes (gene region) that contained at least 1 SNP. When we extended the gene upstream and downstream to 10, 20, 50 and 100 kb, we obtained 30 480, 31 869, 32 754 and 33 223 genes, which contained at least 1 SNP, respectively. The smallest P-value of all SNPs in a gene was chosen to be as the gene-wise risk score. RA-related risk pathways were discovered by permutation test based on Fisher combination method for each of the five gene intervals (0 bp, 10, 20, 50 and 100 kb). The detailed lists of risk pathways identified in each gene interval can be seen in Supplementary Tables S1-S5 (Supporting Information). We calculated frequency scores of the risk pathways whose Q-value was o0.05 after false discovery rate (FDR) correction in each gene interval. The 11 risk pathways whose frequency score is not less than 4 are shown in Table 1 . In these pathways, six risk pathways were reported to be associated with RA in previous literatures. 6, 17, 18, 20 This indicated that this method is effective on identifying the RA-risk pathways. Same results from GAW16 and WTCCC data set The different data sets of the same disease should reflect the common genetic variation of the disease. Thus, we thought that the same pathways that were identified together in the two data sets based on the same disease might be high-risk pathways. We applied pathway-based genome-wide association analysis to two RA data sets and found that there were the same risk pathways identified together in both data sets. We found that the risk pathways were overlapped in the same gene interval in two data sets and listed the same risk pathways in each gene interval in each data set. Next, we calculated frequency scores (frequency appearing in five gene intervals) of the same risk pathways in each data set. On the other hand, we counted the number of same SNPs from 2 SNP data sets after quality control and found that there were~71 132 same SNPs in the 2 data sets, accounting for 14.33% in GAW16 data set and 19.21% in WTCCC data set. We found the overlap percent of the risk pathways in each gene interval of two data sets was more than overlap percent of SNPs. The detailed lists of risk pathways identified together by the two data sets in each gene interval are given in Supplementary Tables S11-S15 (Supporting Information). The frequency scores of the same risk pathways are shown in Supplementary Table S16 (Supporting Information).
There were nine pathways whose frequency score is not less than three (about accounting for 60%). In other word, the nine pathways appeared in no less than three gene intervals in each data set. Thus, they were considered to be high RA-risk pathways. In the nine pathways, extracellular matrix (ECM)-receptor interaction and calcium signaling pathway appeared in each gene interval in GAW16 data set. Focal adhesion appeared in each gene interval in WTCCC data set. Focal adhesion, ECM-receptor interaction, calcium signaling pathway and dopaminergic synapse were reported to be RA-risk pathways in previous studies. Therefore, pathway-based association analysis was effective on identifying high-risk pathways associated with diseases. The detailed information of the nine pathways is shown in Table 3 .
The genes in the focal adhesion pathway were important medium between endothelial cell scaffold and ECM; hence, imbalance of this pathway was closely related to development of RA 22 . Nakano et al. 23 found focal adhesion pathway were hypomethylated pathway of RA. The genes in the focal adhesion pathway such as ITGA, ITGB, Actinin, RTK, Parvin, DOCK1 and BCL2 were enriched with low methylation loci in RA. We also found AkT3, BCL2, COL11A1, EGFR, IGF1, ITGA1, ITGA2, LAMC2, LAMC3, MAPK1, MET, PRKCA, PRKCB, PTK2, RELN, SPP1, TNXB, VAV2, VEGFA and VWFB, which were included as risk genes of autoimmune diseases in genetic association database (GAD) were in this pathway. It indicates that focal adhesion pathway is related to RA. This pathway is shown in Figure 2 . Besides, Böhm et al. 24 found that ADAM15 adds to apoptosis resistance of RA synovial fibroblasts by regulating focal adhesion kinase signaling. As far as we know, inhibition of apoptosis is a cause of arthritis. Thus, the focal adhesion kinase signaling pathway is a target pathway for potential treatment in RA. Shahrara et al. 25 found that focal adhesion kinase family kinases such as focal adhesion kinase and praline-rich kinase 2 are the predominant mediators of integrin αvβ3 signaling events that have an important role in all processes in RA. Activation of the focal adhesion kinase family signaling in RA and osteoarthritic lining cells may be responsible for cell adhesion and migration into the diseased synovial tissues. Taking this novel signaling pathway as a therapy for targeting may be beneficial in RA. These conclusions indicate that focal adhesion pathway is closely related to the development process of RA.
The ECM is composed of a mixture of complex structure and some big functional molecules, and has a role in cell and function maintenance of tissue structure. The interactions between cell and ECM control the activities of the cell indirectly or directly, including cell adhesion, cell migration, cell differentiation, proliferation and cell apoptosis. 26 Ertel et al. 27 reported some switch-like genes, which were related to complex diseases and were enriched in the ECM-receptor interaction and focal adhesion pathway. We also found CD44, COL11A1, ITGA1, ITGA2, LAMC2, LAMC3, RELN, SPP1, SV2B, TNXB and VWF, which were included as risk genes of autoimmune diseases in GAD, were in this pathway. Nakano et al. 23 found ECM-receptor interaction pathway was low methylation pathway of RA. We found ECM-receptor interaction pathway is an RA-risk pathway again.
Calcium signal is crucial to many cellular functions in the immune system. Reduction of calcium in cells will decrease or 
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Abbreviations: FDR, false discovery rate; WTCCC, Wellcome Trust Case Control Consortium. √: This pathway was identified in this gene interval. Pathway-based association analysis M-M Zhang et al prevent the activation and proliferation of immune cell. Especially, calcium signal has an important role in immune response. In the lymphocytes, continuous entrance of calcium ions is necessary to activate phosphatase for a long time in activated T-cell pathways. [28] [29] [30] RA is an autoimmune disease; thus, we infer calcium signal in the body may be related to etiology of RA. Some RA-risk genes included in GAD, such as NOS2, CHRM3, ERBB3, RYR2, HTR2A and PRKCB, are in the calcium signaling pathway. Other 11 risk genes of autoimmune diseases included in GAD are also in this pathway. Besides, RyR, CD38, CaV1 and ROC, which are closely related to RA, are also in this pathway. CD38 glycoprotein exists in immune cell surface and it is associated with calcium ions into the cell. Davies and Hallett 31 found cytosolic calcium ion signal can cause the reactions of neutrophil in RA. Lu et al. 32 also pointed out calcium signaling pathway may be related to heat pattern of RA. Zhang et al. 33 investigated into the pharmacological mechanisms of traditional Chinese medicine acting on RA by integrating network analysis and found that the predicted effector molecules of traditional Chinese medicine were significantly enriched in calcium signaling pathway. It indicates that calcium signaling pathway is target pathway of RA treatment. 33 The other five pathways are not reported as RA-risk pathways in the literature at present. However, we found some possible correlations between them and RA through literature reviews.
Long-term potentiation is a long-lasting enhancement in signal transmission between two neuronsthat results from stimulating them synchronously. 34 Alterations in long-term potentiation may contribute to a number of neurological diseases, including depression, Parkinson's disease, epilepsy and neuropathic pain. 35 Crupi et al. indicated that anxiety was related to autoimmune diseases, such as systemic lupus erythematosus, RA and so on. 36 We found five risk genes of autoimmune diseases, which were CAMK2D, ITPR1, MAPK1, PRKCA and PRKCB, in this pathway. This pathway was also identified as a RA-risk pathway by another of our research about identification of autoimmune disease subpathways.
Some pervious studies had demonstrated a drastic increase in endogenous levels of both glutamic acid (Glu) and aspartate in the synovial fluid obtained from patients with RA. Glu can stimulate the proliferation rate in synovial fibroblasts from model rats, but not in those from normal rats. It was widely believed that primary proliferation of synovial fibroblasts had a key role in the pathogenesis of RA. [37] [38] [39] Overgrowth of synovial fibroblasts could cause cartilage and bone destruction in the joint. 40 Five risk genes of autoimmune diseases included in GAD which are ITPR1, MAPK1, PRKCA, PRKCB and SLC1A7 are in glutamatergic synapse pathway. Thus, we infer glutamatergic synapse pathway may be involved in pathophysiology of RA.
By comparing with the GAD, we found that there were nine risk genes of autoimmune diseases in cholinergic synapse pathway, eight risk genes of autoimmune diseases in dopaminergic synapse pathway, seven risk genes in retrograde endocannabinoid signaling pathway and five risk genes in morphine addiction pathway. The detailed results are given in Supplementary Table S17 (Supporting Information).
DISCUSSION
At present, the pathogenesis and etiology of RA are studied continually. Although some RA-related genetic variations had been discovered, they cannot explain molecular mechanism of RA fully. 41, 42 We thought that cumulative effect of all risk genes in a pathway made the pathway to have an important role in the development of RA. We also thought that different data sets of one disease could reflect the common genetic variation of the disease. Therefore, we applied pathway-based genome-wide association analysis to two RA data sets from GAW16 and WTCCC to identify RA-risk pathways. The same pathways that were identified together by the two data sets were considered as high- Figure 2 . The focal adhesion pathway where autoimmune disease risk genes were annotated. The risk genes of autoimmune disease were colored dark gray and human genes were colored light gray.
risk pathways of RA. They can help us to explain the pathogenesis of RA from the perspective of biological functions. We identified nine pathways that appeared in no less than three intervals as high-risk pathways with RA, four of which had been reported to be associated with RA in previous literatures. The further research of other five pathways may help us to find the relationship between these pathways and RA.
The crucial step was the integration of P-value of each SNP in the gene to represent the gene-wise risk score with the disease in pathway-based association analysis. 10 In this study, we chose the most significant SNP within a gene to represent the gene-wise risk score, as the smallest P-value method reflected the gene association with the disease better. After combination the P-values of SNPs within the gene, the previous genetic studies about RA did gene screening according to threshold. 41 Here we took all genes that contained SNPs as candidate genes for pathway analysis. There were two main reasons. First, the significant genes that surpassed the threshold usually had main effect on RA and only provided limited understanding about etiology of RA. Second, if genes were screened according to threshold, the modest genes that lack statistical significance and the interactions between genes would be ignored. The pathways that contained most of modest genes were hardly identified.
We analyzed the non-randomness of overlapping risk pathways from the two data sets in every gene interval. In each gene interval, we randomly chose the same number of pathways from 237 pathways as the number of pathways identified by each data set and then calculated the number of overlapping pathways from two data sets. We repeated this process 10 000 times to achieve sufficient randomization. The results showed that the overlap of risk pathways identified by two data sets in each gene interval is non-random. It indicated that our results were stable. The risk pathways identified jointly by the two data sets were high-risk pathways associated with RA.
Linkage disequilibrium (LD) is an important issue that should be considered in pathway analysis. Taking into account LD may affect the results;thus, we should do LD correction. The two data sets that we used are not raw SNP genotype data; we only have summary statistics data. One thousand genome data are not only high density but also has the population corresponding to the two data sets. Thus, we use 1000 genomes data from Europe to correct the LD. The detailed information is shown in Supplementary Information. We compared the results after LD correction with the results before LD correction and found that there was no significant difference in RA-risk pathways. The Q-value of every pathway is increased in each gene interval after LD correction. When the threshold of Q-value (FDR) is 0.05, there are six pathways (pathway ID: hsa04728, hsa04724, hsa04723, hsa05032, hsa04725 and hsa04512) to be identified as RA-risk pathways. These six pathways were also identified before LD correction and most of them are not reported as RA-risk pathways in pervious literatures. Thus, further study about the six pathways will help us to explain the pathogenesis of RA. When the threshold of Q-value (FDR) is 0.09, all nine pathways that were identified before LD correction are also RA-risk pathways after LD correction. The detailed results are given in Supplementary Tables S1-S15 (Supplementary Information). This shows that LD correction makes the results become more rigorous and more reliable.
MATERIALS AND METHODS Data
GWAS SNP data come from GAW16 and WTCCC RA data. The GAW16 data set were from the North American Rheumatoid Arthritis Consortiumin 2008, including 5 44 902 autosomal SNPs for 2062 subjects (868 cases and 1194 controls). WTCCC RA data included 459 446 autosomal SNPs for 12 468 subjects (1860 cases and 10 608 controls). The individuals from these two data sets are from the same origin. All of them are Caucasian.
SNPs with minor allele frequency o0.01 or a P-value o0.001 for Hardy-Weinberg equilibrium, or genotype percent o 0.25 were excluded from the analysis. 18 After quality control, GAW16 data set included 531 027 SNPs and WTCCC data set included 4 48 033 SNPs.
Gene data was obtained from the 'seq_gene' file in the National Center for Biotechnology Information (ftp://ftp.ncbi.nlm.nih.gov/genomes/Map View/Homo_sapiens/sequence/BUILD.37.3/). We extracted information of 34 402 autosomal genes, including 'chromosome ID', 'gene start position', 'gene end position', 'gene ID', 'chromosome start position' and 'chromosome end position'. The information can help SNPs mapping to genes.
Pathway data were obtained from KEGG (Kyoto Encyclopedia of Gene and Genomes). The KEGG pathway database had been widely used for the systematic analysis of gene functions that involve molecular interaction in complex diseases. [43] [44] [45] To reduce the impact of multiple testing and avoid testing overly narrow or broad function categories, we selected 237 human KEGG pathways that contained at least 5 and at most 200 genes. 46 We took a pathway as a basic unit of analysis to find biology functions related to RA.
Single locus-based association analysis
We got some information about all SNPs after QC (assume two alleles were x and y), including the numbers of 'case_ xx', 'case_ xy', 'case_ yy', 'control_ xx', 'control_ xy' and 'control_ yy'. We used the Cochran-Armitage trend test to calculate P-values of all SNPs in the GAW16 and WTCCC data sets. 47 See part I of the workflow (Figure 3) .
Mapping SNPs to genes
After obtaining the risk information of SNP, we mapped SNPs to genes according to position information of SNPs. 'SNP ID', 'chromosome No.' and 'SNP location' were written in SNP annotation file. We mapped an SNP to a gene if it was located within the gene upstream or downstream. To make the results more reliable, genes upstream and downstream were extended 10, 20, 50 and 100 kb. All SNPs of every data set were mapped to 34 402 autosomal genes and their extended gene intervals, respectively. See part II of the workflow (Figure 3 ).
Assessing gene-wise risk score
For the genes where SNPs exist after mapping, the smallest χ 2 -trend statistic P-value in this gene was chosen to assess the gene-wise risk score in the gene. 48, 49 For example, we assume that there were m SNPs in the Figure 3 . The workflow of this study.
Pathway-based association analysis
i-th gene after mapping and we chose the smallest P-value of all SNPs to represent gene-wise risk score, that is,
where R i is the risk score of the i-th gene with RA, p ij is P-value of the j-th SNP in the i-th gene, j = 1,2⋯, m.
Calculating pathway risk score Each pathway was composed of genes; thus, e calculated pathway risk scores based on gene-wise risk scores. We adopted two methods to calculate 237 pathway risk scores. Fisher combination method: we assume that there are n genes that have gene-wise risk scores in the k-th pathway.
where S k is the risk score of the k-th pathway, n is the number of genes in the k-th pathway and R ki is the gene-wise risk score of the i-th gene with RA in the k-th pathway. 5, 50 Adjustment Fisher combination method: we assume that there are n genes that have gene-wise risk scores in the k-th pathway.
where S′ k is the risk score of the k-th pathway, n is the number of genes in the k-th pathway and R ki is the gene-wise risk score of the i-th gene with RA in the k-th pathway.
Permutation test
Permutation test is usually used to estimate whether the true value is different from the background distribution. In this study, to further evaluate whether a pathway was significantly associated with RA, we performed permutation test by shuffling the pathway labels. The null hypothesis is that there is no association between the pathway and RA. We counted the number of non-redundant genes in the 237 pathways and adopted two methods to do permutation test.
Permutation test based on Fisher combination method
We counted the number of non-redundant genes that had association scores in all 237 pathways and denoted it as M1. Next, we calculated the 237 pathway scores by equation (1) . Specifically, for a pathway, we recorded the number of genes involved in calculation this pathway score and denoted the pathway score as S true . Next, we randomly chose the same number of genes as the number of genes involved in the calculation of this pathway score from M1, calculated the random pathway score by equation (1) and denoted it as S random . We repeated this process for 1 00 000 times to achieve sufficient randomization. The resultant S random formed an estimated background distribution of this pathway. The smaller the P-value of SNP, the gene-wise risk score is greater. The greater the pathway score, the more associated the pathway is with RA. A P permutation was computed for each pathway by counting the number of permutations that have S random more than S true , divided by the total number of permutations, that is, P permutation ¼ fno: of S random 4S true g ftotal no: of permutationsg ð3Þ
Permutation test based on adjusted Fisher combination method
We counted the number of non-redundant genes in all 237 pathways and denoted it as M2. Next, we calculated the 237 pathway scores by equation (2) . Specifically, for a pathway, we recorded the number of genes in this pathway and denoted the pathway score as S true . Next, we randomly chose the same number of genes from M2, calculated the random pathway score by equation (2) and denoted it as S random . We repeated this process for 1 00 000 times to achieve sufficient randomization.
Multiple testing corrections
Multiple hypothesis tests had been used to identify pathways related to RA, but they could increase of type I error and false-positive error rate.
Thus, we adopted multiple testing corrections to solve this problem. A threshold 0.05 of Q-value (FDR) was used to identify RA-risk pathways.
